Drugs interactions for Invokana®
- 64 Major drug interactions (including ingredients like Abametapir, Abemaciclib, Amiodarone)
- 468 Moderate drug interactions (including ingredients like Abrocitinib, Acarbose, Acebutolol)
- 420 Minor drug interactions (including ingredients like Abacavir, Abaloparatide, Aceclofenac)
952 interactions for Invokana®The serum concentration of Canagliflozin can be increased when it is combined with Abametapir.The serum concentration of Abemaciclib can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Amiodarone.The metabolism of Canagliflozin can be decreased when combined with Atazanavir.The serum concentration of Axitinib can be increased when it is combined with Canagliflozin.The serum concentration of Bendamustine can be increased when it is combined with Canagliflozin.The serum concentration of Binimetinib can be increased when it is combined with Canagliflozin.The serum concentration of Bortezomib can be increased when it is combined with Canagliflozin.The serum concentration of Cabergoline can be increased when it is combined with Canagliflozin.The serum concentration of Carfilzomib can be increased when it is combined with Canagliflozin.The serum concentration of Ceritinib can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Clarithromycin.The serum concentration of Cobimetinib can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Conivaptan.The serum concentration of Crizotinib can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Curcumin.The serum concentration of Cyclosporine can be increased when it is combined with Canagliflozin.The serum concentration of Dacomitinib can be increased when it is combined with Canagliflozin.The serum concentration of Dactinomycin can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Danazol.The metabolism of Canagliflozin can be decreased when combined with Darunavir.The serum concentration of Dasatinib can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Elvitegravir.The metabolism of Canagliflozin can be decreased when combined with Ergotamine.The serum concentration of Etoposide can be increased when it is combined with Canagliflozin.The serum concentration of Gemcitabine can be increased when it is combined with Canagliflozin.The serum concentration of Imipramine can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Indinavir.The metabolism of Canagliflozin can be decreased when combined with Itraconazole.The metabolism of Canagliflozin can be decreased when combined with Ketoconazole.The metabolism of Canagliflozin can be decreased when combined with Levoketoconazole.The metabolism of Canagliflozin can be decreased when combined with Lonafarnib.The metabolism of Canagliflozin can be decreased when combined with Lopinavir.The metabolism of Canagliflozin can be decreased when combined with Methimazole.The metabolism of Canagliflozin can be decreased when combined with Midostaurin.The metabolism of Canagliflozin can be increased when combined with Mitotane.The metabolism of Canagliflozin can be decreased when combined with Nefazodone.The metabolism of Canagliflozin can be decreased when combined with Nelfinavir.The metabolism of Canagliflozin can be decreased when combined with Nilotinib.The serum concentration of Nortriptyline can be increased when it is combined with Canagliflozin.The serum concentration of Osimertinib can be increased when it is combined with Canagliflozin.The serum concentration of Panobinostat can be increased when it is combined with Canagliflozin.The serum concentration of Pomalidomide can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Posaconazole.The serum concentration of Quinidine can be increased when it is combined with Canagliflozin.The serum concentration of Regorafenib can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Ribociclib.The metabolism of Canagliflozin can be increased when combined with Rifapentine.The serum concentration of Rimegepant can be increased when it is combined with Canagliflozin.The serum concentration of Romidepsin can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Saquinavir.The excretion of Silodosin can be decreased when combined with Canagliflozin.The serum concentration of Sirolimus can be increased when it is combined with Canagliflozin.The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Spironolactone.The metabolism of Canagliflozin can be decreased when combined with Telithromycin.The serum concentration of Temsirolimus can be increased when it is combined with Canagliflozin.The serum concentration of Tepotinib can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Tipranavir.The serum concentration of Tolvaptan can be increased when it is combined with Canagliflozin.The serum concentration of Trastuzumab emtansine can be increased when it is combined with Canagliflozin.The serum concentration of Trimipramine can be increased when it is combined with Canagliflozin.The serum concentration of Venetoclax can be increased when it is combined with Canagliflozin.The serum concentration of Vinblastine can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Voriconazole.The serum concentration of Canagliflozin can be increased when it is combined with Abrocitinib.Canagliflozin may increase the hypoglycemic activities of Acarbose.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Acebutolol.The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Adagrasib.The serum concentration of Afatinib can be increased when it is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Canagliflozin.Canagliflozin may increase the hypoglycemic activities of Alogliptin.The serum concentration of Ambrisentan can be increased when it is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Amikacin which could result in a higher serum level.Aminosalicylic acid may increase the hypoglycemic activities of Canagliflozin.Amitriptyline may decrease the hypoglycemic activities of Canagliflozin.The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Canagliflozin.The serum concentration of Canagliflozin can be decreased when it is combined with Amobarbital.Amoxapine may decrease the hypoglycemic activities of Canagliflozin.The serum concentration of Canagliflozin can be decreased when it is combined with Apalutamide.The serum concentration of Apixaban can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Aprepitant.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Aripiprazole.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Arsenic trioxide.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Articaine.The serum concentration of Canagliflozin can be increased when it is combined with Asciminib.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Asenapine.The serum concentration of Canagliflozin can be increased when it is combined with Asunaprevir.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Atenolol.The serum concentration of Avanafil can be increased when it is combined with Canagliflozin.The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Azilsartan medoxomil.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Baclofen.Balsalazide may increase the hypoglycemic activities of Canagliflozin.The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Canagliflozin.The serum concentration of Belinostat can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Belumosudil.The risk or severity of hypoglycemia can be increased when Benazepril is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Bendroflumethiazide.The serum concentration of Berotralstat can be increased when it is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Betaxolol.The serum concentration of Betrixaban can be increased when it is combined with Canagliflozin.Canagliflozin may increase the hypoglycemic activities of Bexagliflozin.Bismuth subsalicylate may increase the hypoglycemic activities of Canagliflozin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Bisoprolol.The serum concentration of Bosutinib can be increased when it is combined with Canagliflozin.The serum concentration of Brentuximab vedotin can be increased when it is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Brexpiprazole.Canagliflozin may increase the hypoglycemic activities of Bromocriptine.The risk or severity of hyperglycemia can be increased when Budesonide is combined with Canagliflozin.The risk or severity of hypotension can be increased when Canagliflozin is combined with Bumetanide.The serum concentration of Canagliflozin can be decreased when it is combined with Butalbital.The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Candesartan cilexetil.The metabolism of Canagliflozin can be decreased when combined with Cannabidiol.The serum concentration of Canagliflozin can be increased when it is combined with Capmatinib.Canagliflozin may decrease the excretion rate of Capreomycin which could result in a higher serum level.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Captopril.The metabolism of Canagliflozin can be increased when combined with Carbamazepine.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Carvedilol.The serum concentration of Canagliflozin can be decreased when it is combined with Cenobamate.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorothiazide.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorpromazine.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorthalidone.Choline salicylate may increase the hypoglycemic activities of Canagliflozin.The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Ciprofloxacin.Canagliflozin may decrease the excretion rate of Cisplatin which could result in a higher serum level.The risk or severity of hypoglycemia can be increased when Citalopram is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Canagliflozin.The serum concentration of Clobazam can be increased when it is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Canagliflozin.The serum concentration of Clomifene can be increased when it is combined with Canagliflozin.Clomipramine may decrease the hypoglycemic activities of Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Clozapine.The serum concentration of Canagliflozin can be increased when it is combined with Cobicistat.The serum concentration of Colchicine can be increased when it is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Colistin which could result in a higher serum level.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Conjugated estrogens.The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Canagliflozin.The serum concentration of Dabigatran etexilate can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be decreased when it is combined with Dabrafenib.The serum concentration of Canagliflozin can be increased when it is combined with Danicopan.Dapagliflozin may increase the hypoglycemic activities of Canagliflozin.The serum concentration of Daptomycin can be increased when it is combined with Canagliflozin.The serum concentration of Darolutamide can be increased when it is combined with Canagliflozin.The serum concentration of Dasabuvir can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Deferasirox.The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Delafloxacin.Desipramine may decrease the hypoglycemic activities of Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Desogestrel.The risk or severity of hyperglycemia can be increased when Desonide is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Dexamethasone acetate is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Diazoxide.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dienogest.The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Canagliflozin.Diflunisal may increase the hypoglycemic activities of Canagliflozin.The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Canagliflozin.The serum concentration of Digoxin can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Diltiazem.The serum concentration of Canagliflozin can be increased when it is combined with Diosmin.Dipotassium phosphate may increase the hyperkalemic activities of Canagliflozin.Canagliflozin may increase the hypoglycemic activities of Disopyramide.The serum concentration of Dolutegravir can be increased when it is combined with Canagliflozin.Doxepin may decrease the hypoglycemic activities of Canagliflozin.The serum concentration of Doxorubicin can be increased when it is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Dronedarone.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Drospirenone.Canagliflozin may increase the hypoglycemic activities of Dulaglutide.The serum concentration of Duvelisib can be increased when it is combined with Canagliflozin.The serum concentration of Edoxaban can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be decreased when it is combined with Efavirenz.The serum concentration of Canagliflozin can be increased when it is combined with Elacestrant.The serum concentration of Elagolix can be increased when it is combined with Canagliflozin.The serum concentration of Elbasvir can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Eliglustat.The metabolism of Canagliflozin can be decreased when combined with Eltrombopag.Canagliflozin may increase the hypoglycemic activities of Empagliflozin.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Enalapril.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Enalaprilat.The serum concentration of Canagliflozin can be increased when it is combined with Enasidenib.The serum concentration of Encorafenib can be increased when it is combined with Canagliflozin.The serum concentration of Enfortumab vedotin can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Entrectinib.The serum concentration of Canagliflozin can be decreased when it is combined with Enzalutamide.The serum concentration of Canagliflozin can be increased when it is combined with Epcoritamab.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Epinephrine.The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Eprosartan.The serum concentration of Canagliflozin can be increased when it is combined with Erdafitinib.Canagliflozin may increase the hypoglycemic activities of Ertugliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Erythromycin.The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Canagliflozin.The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Estetrol.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Estradiol.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Estrone sulfate.The risk or severity of hypotension can be increased when Canagliflozin is combined with Etacrynic acid.Ethanol may increase the hypotensive activities of Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ethinylestradiol.The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ethynodiol diacetate.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Etonogestrel.The serum concentration of Everolimus can be increased when it is combined with Canagliflozin.Canagliflozin may increase the hypoglycemic activities of Exenatide.The serum concentration of Canagliflozin can be increased when it is combined with Fedratinib.The risk or severity of hypoglycemia can be increased when Felodipine is combined with Canagliflozin.The serum concentration of Fexofenadine can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Flibanserin.The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Fluconazole.The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Fosamprenavir.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Fosinopril.The metabolism of Canagliflozin can be decreased when combined with Fosnetupitant.The serum concentration of Canagliflozin can be decreased when it is combined with Fosphenytoin.The serum concentration of Fostemsavir can be increased when it is combined with Canagliflozin.The risk or severity of hypotension can be increased when Canagliflozin is combined with Furosemide.The metabolism of Canagliflozin can be decreased when combined with Fusidic acid.The serum concentration of Futibatinib can be increased when it is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Gatifloxacin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Gemifloxacin.Canagliflozin may decrease the excretion rate of Gentamicin which could result in a higher serum level.The serum concentration of Gilteritinib can be increased when it is combined with Canagliflozin.The serum concentration of Glasdegib can be increased when it is combined with Canagliflozin.The serum concentration of Glecaprevir can be increased when it is combined with Canagliflozin.Canagliflozin may increase the hypoglycemic activities of Glimepiride.Canagliflozin may increase the hypoglycemic activities of Glipizide.The serum concentration of Canagliflozin can be increased when it is combined with Glofitamab.Canagliflozin may increase the hypoglycemic activities of Glyburide.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Goserelin.The serum concentration of Grazoprevir can be increased when it is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Canagliflozin.The serum concentration of Haloperidol can be increased when it is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Histrelin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydrochlorothiazide.The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydroflumethiazide.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Hydroxychloroquine.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydroxyprogesterone caproate.The serum concentration of Idelalisib can be increased when it is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Iloperidone.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Indapamide.The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Insulin aspart is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Insulin degludec is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Insulin detemir is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Insulin glulisine is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Insulin human is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Canagliflozin.The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Irbesartan.The serum concentration of Canagliflozin can be increased when it is combined with Isavuconazonium.Isocarboxazid may increase the orthostatic hypotensive activities of Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Isoniazid.The metabolism of Canagliflozin can be decreased when combined with Isradipine.The serum concentration of Canagliflozin can be increased when it is combined with Istradefylline.The serum concentration of Canagliflozin can be increased when it is combined with Ivacaftor.The metabolism of Canagliflozin can be increased when combined with Ivosidenib.The serum concentration of Canagliflozin can be increased when it is combined with Ixabepilone.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Labetalol.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lanreotide.The serum concentration of Canagliflozin can be increased when it is combined with Lapatinib.The serum concentration of Canagliflozin can be increased when it is combined with Lasmiditan.The serum concentration of Ledipasvir can be increased when it is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Lefamulin which could result in a higher serum level.The serum concentration of Lemborexant can be increased when it is combined with Canagliflozin.The serum concentration of Lenacapavir can be increased when it is combined with Canagliflozin.The serum concentration of Lenvatinib can be increased when it is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Leuprolide.The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Levofloxacin.The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Levonorgestrel.Canagliflozin may increase the hypoglycemic activities of Linagliptin.Linezolid may increase the orthostatic hypotensive activities of Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Liothyronine.The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Canagliflozin.Canagliflozin may increase the hypoglycemic activities of Liraglutide.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Lisinopril.Canagliflozin may increase the hypoglycemic activities of Lixisenatide.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Lomefloxacin.The serum concentration of Canagliflozin can be increased when it is combined with Lomitapide.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lonapegsomatropin.The serum concentration of Loncastuximab tesirine can be increased when it is combined with Canagliflozin.The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Losartan.The serum concentration of Canagliflozin can be increased when it is combined with Loxapine.The serum concentration of Canagliflozin can be decreased when it is combined with Lumacaftor.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lurasidone.The serum concentration of Lusutrombopag can be increased when it is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Canagliflozin.The serum concentration of Mannitol can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Maribavir.The serum concentration of Canagliflozin can be decreased when it is combined with Mavacamten.The excretion of Mavorixafor can be decreased when combined with Canagliflozin.Canagliflozin may increase the hypoglycemic activities of Mecasermin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.The risk or severity of hyperglycemia can be increased when Medrysone is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Mefenamic acid.The serum concentration of Canagliflozin can be increased when it is combined with Mefloquine.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Megestrol acetate.Mesalazine may increase the hypoglycemic activities of Canagliflozin.The serum concentration of Canagliflozin can be decreased when it is combined with Methohexital.The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Canagliflozin.Methyl salicylate may increase the hypoglycemic activities of Canagliflozin.Methylene blue may increase the orthostatic hypotensive activities of Canagliflozin.The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Metolazone.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Metoprolol.The metabolism of Canagliflozin can be decreased when combined with Miconazole.The serum concentration of Midazolam can be increased when it is combined with Canagliflozin.Canagliflozin may increase the hypoglycemic activities of Mifepristone.Canagliflozin may increase the hypoglycemic activities of Miglitol.The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Mirabegron.The serum concentration of Canagliflozin can be increased when it is combined with Mitapivat.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Moexipril.The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Canagliflozin.Monopotassium phosphate may increase the hyperkalemic activities of Canagliflozin.The serum concentration of Morphine can be increased when it is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Moxifloxacin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Nadolol.The serum concentration of Naloxegol can be increased when it is combined with Canagliflozin.Canagliflozin may increase the hypoglycemic activities of Nateglinide.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Nebivolol.Canagliflozin may decrease the excretion rate of Neomycin which could result in a higher serum level.The serum concentration of Canagliflozin can be increased when it is combined with Neratinib.The metabolism of Canagliflozin can be decreased when combined with Netupitant.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Niacin.The metabolism of Canagliflozin can be decreased when combined with Nicardipine.The risk or severity of hypoglycemia can be increased when Nifedipine is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Canagliflozin.The serum concentration of Nintedanib can be increased when it is combined with Canagliflozin.The serum concentration of Nirogacestat can be increased when it is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Norethisterone.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Norgestimate.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Octreotide.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Ofloxacin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Olanzapine.The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Olmesartan.Olsalazine may increase the hypoglycemic activities of Canagliflozin.The serum concentration of Omadacycline can be increased when it is combined with Canagliflozin.The serum concentration of Ombitasvir can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Pacritinib.The serum concentration of Canagliflozin can be increased when it is combined with Palbociclib.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Paliperidone.The serum concentration of Paritaprevir can be increased when it is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pasireotide.The serum concentration of Pazopanib can be increased when it is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.Canagliflozin may increase the hypoglycemic activities of Pentamidine.The serum concentration of Canagliflozin can be decreased when it is combined with Pentobarbital.Canagliflozin may decrease the excretion rate of Pentostatin which could result in a higher serum level.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Perindopril.Phenelzine may increase the orthostatic hypotensive activities of Canagliflozin.The serum concentration of Canagliflozin can be decreased when it is combined with Phenobarbital.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Phentermine.The serum concentration of Canagliflozin can be decreased when it is combined with Phenytoin.The serum concentration of Pibrentasvir can be increased when it is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Pindolol.Canagliflozin may increase the hypoglycemic activities of Pioglitazone.The serum concentration of Canagliflozin can be increased when it is combined with Piperine.The serum concentration of Canagliflozin can be increased when it is combined with Pirtobrutinib.The serum concentration of Canagliflozin can be decreased when it is combined with Pitolisant.Canagliflozin may decrease the excretion rate of Plazomicin which could result in a higher serum level.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Polythiazide.The serum concentration of Canagliflozin can be increased when it is combined with Ponatinib.Potassium may increase the hyperkalemic activities of Canagliflozin.Potassium acetate may increase the hyperkalemic activities of Canagliflozin.Potassium bicarbonate may increase the hyperkalemic activities of Canagliflozin.Potassium bitartrate may increase the hyperkalemic activities of Canagliflozin.Potassium carbonate may increase the hyperkalemic activities of Canagliflozin.Potassium cation may increase the hyperkalemic activities of Canagliflozin.Potassium chloride may increase the hyperkalemic activities of Canagliflozin.Potassium citrate may increase the hyperkalemic activities of Canagliflozin.Potassium hydroxide may increase the hyperkalemic activities of Canagliflozin.Potassium Iodide may increase the hyperkalemic activities of Canagliflozin.Potassium nitrate may increase the hyperkalemic activities of Canagliflozin.Potassium sulfate may increase the hyperkalemic activities of Canagliflozin.Potassium triiodide may increase the hyperkalemic activities of Canagliflozin.The serum concentration of Pralsetinib can be increased when it is combined with Canagliflozin.Canagliflozin may increase the hypoglycemic activities of Pramlintide.The serum concentration of Pravastatin can be increased when it is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Prednisone is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Pretomanid.The metabolism of Canagliflozin can be decreased when combined with Primaquine.The serum concentration of Canagliflozin can be decreased when it is combined with Primidone.Canagliflozin may decrease the excretion rate of Procainamide which could result in a higher serum level.Procaine may increase the orthostatic hypotensive activities of Canagliflozin.Procarbazine may increase the orthostatic hypotensive activities of Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Progesterone.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Propafenone.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Propranolol.Protriptyline may decrease the hypoglycemic activities of Canagliflozin.The serum concentration of Prucalopride can be increased when it is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pseudoephedrine.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Quetiapine.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Quinapril.Canagliflozin may increase the hypoglycemic activities of Quinine.The serum concentration of Quizartinib can be increased when it is combined with Canagliflozin.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Ramipril.The serum concentration of Ranolazine can be increased when it is combined with Canagliflozin.Rasagiline may increase the orthostatic hypotensive activities of Canagliflozin.The serum concentration of Relugolix can be increased when it is combined with Canagliflozin.Canagliflozin may increase the hypoglycemic activities of Repaglinide.The serum concentration of Repotrectinib can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Reserpine.The serum concentration of Revefenacin can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be decreased when it is combined with Rifampicin.The serum concentration of Rifaximin can be increased when it is combined with Canagliflozin.The serum concentration of Riociguat can be increased when it is combined with Canagliflozin.The serum concentration of Ripretinib can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Ritlecitinib.The metabolism of Canagliflozin can be increased when combined with Ritonavir.The serum concentration of Rivaroxaban can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Rolapitant.Canagliflozin may increase the hypoglycemic activities of Rosiglitazone.Safinamide may increase the orthostatic hypotensive activities of Canagliflozin.Salicylic acid may increase the hypoglycemic activities of Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Sapropterin.The serum concentration of Canagliflozin can be increased when it is combined with Sarecycline.The serum concentration of Canagliflozin can be decreased when it is combined with Satralizumab.Canagliflozin may increase the hypoglycemic activities of Saxagliptin.The serum concentration of Canagliflozin can be decreased when it is combined with Secobarbital.Selegiline may increase the orthostatic hypotensive activities of Canagliflozin.The serum concentration of Selexipag can be increased when it is combined with Canagliflozin.The serum concentration of Selumetinib can be increased when it is combined with Canagliflozin.Canagliflozin may increase the hypoglycemic activities of Semaglutide.The risk or severity of hypoglycemia can be increased when Sertraline is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Sildenafil.The serum concentration of Canagliflozin can be increased when it is combined with Simvastatin.Canagliflozin may increase the hypoglycemic activities of Sitagliptin.The risk or severity of hypotension can be increased when Sodium ferric gluconate complex is combined with Canagliflozin.Sodium phosphate, monobasic may increase the hyperkalemic activities of Canagliflozin.The serum concentration of Sofosbuvir can be increased when it is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Somapacitan.Somatotropin may decrease the hypoglycemic activities of Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Somatrogon.The serum concentration of Canagliflozin can be increased when it is combined with Sorafenib.Canagliflozin may increase the hypoglycemic activities of Sotagliflozin.The risk or severity of hypoglycemia can be increased when Sotalol is combined with Canagliflozin.The serum concentration of Canagliflozin can be decreased when it is combined with Sotorasib.The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Sparsentan.The metabolism of Canagliflozin can be decreased when combined with Stiripentol.Canagliflozin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Canagliflozin may increase the hypoglycemic activities of Sulfadiazine.Canagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.Sulfasalazine may increase the hypoglycemic activities of Canagliflozin.Canagliflozin may increase the hypoglycemic activities of Sunitinib.The serum concentration of Canagliflozin can be increased when it is combined with Suvorexant.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tacrolimus.The serum concentration of Canagliflozin can be increased when it is combined with Tamoxifen.The serum concentration of Tazemetostat can be increased when it is combined with Canagliflozin.The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Canagliflozin.The serum concentration of Tegaserod can be increased when it is combined with Canagliflozin.The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Telmisartan.The serum concentration of Canagliflozin can be decreased when it is combined with Telotristat ethyl.The serum concentration of Tenofovir alafenamide can be increased when it is combined with Canagliflozin.The serum concentration of Tenofovir disoproxil can be increased when it is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Teprotumumab.The serum concentration of Tezacaftor can be increased when it is combined with Canagliflozin.Thyroid, porcine may decrease the hypoglycemic activities of Canagliflozin.Thyrotropin alfa may decrease the hypoglycemic activities of Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Ticagrelor.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Timolol.Canagliflozin may increase the hypoglycemic activities of Tirzepatide.The serum concentration of Tivozanib can be increased when it is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Tobramycin which could result in a higher serum level.Canagliflozin may increase the hypoglycemic activities of Tolazamide.The serum concentration of Topotecan can be increased when it is combined with Canagliflozin.The risk or severity of hypotension can be increased when Canagliflozin is combined with Torasemide.The serum concentration of Canagliflozin can be increased when it is combined with Toremifene.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Trandolapril.Tranylcypromine may increase the orthostatic hypotensive activities of Canagliflozin.The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Canagliflozin.The serum concentration of Trilaciclib can be increased when it is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Triptorelin.Trolamine salicylate may increase the hypoglycemic activities of Canagliflozin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Trovafloxacin.Tucatinib may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Canagliflozin.The serum concentration of Ubrogepant can be increased when it is combined with Canagliflozin.The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Canagliflozin.The serum concentration of Umeclidinium can be increased when it is combined with Canagliflozin.The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Valsartan.The risk or severity of hyperglycemia can be increased when Vamorolone is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Vancomycin which could result in a higher serum level.The serum concentration of Canagliflozin can be increased when it is combined with Vandetanib.The serum concentration of Canagliflozin can be increased when it is combined with Vardenafil.The serum concentration of Velpatasvir can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Vemurafenib.The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Canagliflozin.The metabolism of Canagliflozin can be decreased when combined with Verapamil.The serum concentration of Canagliflozin can be increased when it is combined with Vimseltinib.The excretion of Vincristine can be decreased when combined with Canagliflozin.The serum concentration of Voclosporin can be increased when it is combined with Canagliflozin.The serum concentration of Canagliflozin can be increased when it is combined with Vorapaxar.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Vorinostat.The serum concentration of Voxilaprevir can be increased when it is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Warfarin which could result in a higher serum level.The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Canagliflozin.The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ziprasidone.The serum concentration of Canagliflozin can be increased when it is combined with Zonisamide.Abacavir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Abaloparatide is combined with Canagliflozin.The risk or severity of hyperkalemia can be increased when Aceclofenac is combined with Canagliflozin.Acetaminophen may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Acetazolamide.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Acetyl sulfisoxazole.Aclidinium may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Acrivastine which could result in a higher serum level.Acyclovir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Adefovir dipivoxil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Albuterol.Canagliflozin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.The risk or severity of adverse effects can be increased when Aldesleukin is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Canagliflozin is combined with Aliskiren.Allopurinol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Almasilate which could result in a higher serum level.Almotriptan may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Alprazolam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Amantadine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Amifostine is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Amiloride is combined with Canagliflozin.The risk or severity of hyperkalemia can be increased when Ammonium chloride is combined with Canagliflozin.Amoxicillin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Amphetamine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Amphotericin B is combined with Canagliflozin.Ampicillin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Canagliflozin.The risk or severity of hyperkalemia can be increased when Antipyrine is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.The risk or severity of adverse effects can be increased when Apomorphine is combined with Canagliflozin.Apremilast may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may increase the hypotensive activities of Aprocitentan.Arformoterol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Aripiprazole lauroxil may increase the hypotensive activities of Canagliflozin.Atomoxetine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Auranofin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Azacitidine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Azathioprine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Azelaic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Aztreonam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Bacitracin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Baricitinib which could result in a higher serum level.Benzatropine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Benznidazole which could result in a higher serum level.Bepotastine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Bicisate which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.Bleomycin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Bosentan.The risk or severity of adverse effects can be increased when Bretylium is combined with Canagliflozin.Brivaracetam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Bromotheophylline may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.The risk or severity of adverse effects can be increased when Bupivacaine is combined with Canagliflozin.Bupropion may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Buspirone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Capecitabine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Carbidopa may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Carboplatin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Carmustine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefaclor may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefadroxil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefazolin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefdinir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefditoren may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefepime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefotaxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefotetan may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefoxitin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefpodoxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefprozil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Ceftaroline fosamil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Ceftazidime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Ceftibuten may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Ceftizoxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Ceftolozane which could result in a higher serum level.Ceftriaxone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cefuroxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Celecoxib is combined with Canagliflozin.Cephalexin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Certolizumab pegol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cetirizine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cevimeline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Chloroquine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Chlorzoxazone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Chromic chloride which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Chromium which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.Cidofovir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cilostazol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cimetidine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Clofarabine is combined with Canagliflozin.Clonazepam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Clonidine is combined with Canagliflozin.Clorazepic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Clove oil which could result in a higher serum level.Colistimethate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Cyanocobalamin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Dacarbazine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Dalfampridine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Dalteparin is combined with Canagliflozin.The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Canagliflozin.Canagliflozin may increase the hypotensive activities of Dasiglucagon.Deferiprone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Desflurane is combined with Canagliflozin.Desmopressin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.Dexrazoxane may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Dextran which could result in a higher serum level.Diatrizoate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Diazepam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Diclofenac is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Diclofenamide is combined with Canagliflozin.Dicyclomine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Didanosine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Dimercaprol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Dimethyl sulfoxide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Canagliflozin is combined with Dinutuximab.The risk or severity of adverse effects can be increased when Dipyridamole is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.Dobutamine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Dopamine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Doxazosin is combined with Canagliflozin.Doxycycline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Droxidopa may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of orthostatic hypotension and syncope can be increased when Canagliflozin is combined with Duloxetine.Edrophonium may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Canagliflozin.The serum concentration of Ensartinib can be increased when it is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Eplerenone is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Epoprostenol is combined with Canagliflozin.Ertapenem may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Esmolol is combined with Canagliflozin.Estazolam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.Eszopiclone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Ethambutol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Ethenzamide.The risk or severity of hyperkalemia can be increased when Etodolac is combined with Canagliflozin.Etomidate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.Fenofibrate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.The risk or severity of adverse effects can be increased when Fenoldopam is combined with Canagliflozin.The risk or severity of hyperkalemia can be increased when Fenoprofen is combined with Canagliflozin.Fentanyl may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Fesoterodine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Finerenone.The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Fish oil.Flavoxate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.Floxuridine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Flucytosine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.Flumazenil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Fluoxymesterone may increase the hypoglycemic activities of Canagliflozin.Flurazepam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Flurbiprofen is combined with Canagliflozin.Flutamide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Folic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Fomepizole may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Fondaparinux may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Foscarnet may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Fosfomycin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of hypotension can be increased when Fostamatinib is combined with Canagliflozin.Gabapentin enacarbil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Gadobenic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Gadodiamide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Gadofosveset trisodium may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.Gadoteridol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Ganciclovir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Gemfibrozil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Givosiran may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Golodirsen which could result in a higher serum level.The risk or severity of adverse effects can be increased when Guanfacine is combined with Canagliflozin.The risk or severity of hyperkalemia can be increased when Heparin is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Hydralazine is combined with Canagliflozin.Hydromorphone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Hydroxocobalamin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Canagliflozin.Ibutilide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Icatibant may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Icosapent is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.Ifosfamide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Iloprost is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Inositol which could result in a higher serum level.Inotersen may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.Iodixanol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Ioflupane I-123 may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Iopromide which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Ioversol which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Ipecac which could result in a higher serum level.Ipilimumab may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Isoflurane is combined with Canagliflozin.Isosorbide may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Isosorbide mononitrate is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.Isotretinoin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Canagliflozin is combined with Isoxsuprine.Canagliflozin may decrease the excretion rate of Ixazomib which could result in a higher serum level.Ketamine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Ketoprofen is combined with Canagliflozin.The risk or severity of hyperkalemia can be increased when Ketorolac is combined with Canagliflozin.The risk or severity of thrombocytopenia can be increased when Canagliflozin is combined with Ketotifen.The serum concentration of Canagliflozin can be increased when it is combined with L-Acetylleucine.Lamivudine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Lamotrigine is combined with Canagliflozin.The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Landiolol.Lenalidomide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Levocarnitine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Levocetirizine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of hypotension and orthostatic hypotension can be increased when Canagliflozin is combined with Levodopa.The risk or severity of hyperkalemia can be increased when Levomenthol is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Levothyroxine.The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lithium carbonate.Lithium citrate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Lofexidine is combined with Canagliflozin.The excretion of Loperamide can be decreased when combined with Canagliflozin.Lorazepam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Lubiprostone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Macitentan which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Magnesium salicylate is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.Maprotiline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Mecamylamine is combined with Canagliflozin.The risk or severity of hyperkalemia can be increased when Meclofenamic acid is combined with Canagliflozin.The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Canagliflozin.Memantine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Meperidine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Mepivacaine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Meropenem may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metamfetamine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Metaxalone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Methadone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Methazolamide is combined with Canagliflozin.Methotrexate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Methoxsalen may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Methyldopa is combined with Canagliflozin.Methylnaltrexone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Methyltestosterone may increase the hypoglycemic activities of Canagliflozin.Metoclopramide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The metabolism of Canagliflozin can be increased when combined with Metreleptin.Metyrapone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may increase the hypotensive activities of Metyrosine.Migalastat may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Milrinone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Minoxidil is combined with Canagliflozin.Mycophenolate mofetil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Mycophenolic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.The risk or severity of adverse effects can be increased when Nabilone is combined with Canagliflozin.The risk or severity of hyperkalemia can be increased when Nabumetone is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Naldemedine which could result in a higher serum level.Nalmefene may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Naloxone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Nandrolone decanoate may increase the hypoglycemic activities of Canagliflozin.The risk or severity of hyperkalemia can be increased when Naproxen is combined with Canagliflozin.Nedocromil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Nilutamide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Canagliflozin.The risk or severity of hyperkalemia can be increased when Nitrofurantoin is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Nitroprusside is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Canagliflozin is combined with Nitrous acid.The risk or severity of adverse effects can be increased when Canagliflozin is combined with Obinutuzumab.Canagliflozin may decrease the excretion rate of Octinoxate which could result in a higher serum level.The serum concentration of Canagliflozin can be decreased when it is combined with Omaveloxolone.The risk or severity of adverse effects can be increased when Canagliflozin is combined with Opicapone.Canagliflozin may decrease the excretion rate of Opium which could result in a higher serum level.Oseltamivir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Oxacillin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Oxandrolone may increase the hypoglycemic activities of Canagliflozin.The risk or severity of hyperkalemia can be increased when Oxaprozin is combined with Canagliflozin.Oxazepam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Oxybenzone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Oxymetholone may increase the hypoglycemic activities of Canagliflozin.Canagliflozin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.The risk or severity of adverse effects can be increased when Paclitaxel is combined with Canagliflozin.Palonosetron may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Pamidronic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Pantoprazole may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Papaverine is combined with Canagliflozin.The risk or severity of hyperkalemia can be increased when Parecoxib is combined with Canagliflozin.Paromomycin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Pentetic acid which could result in a higher serum level.Pentoxifylline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Permethrin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Phenazopyridine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Phentolamine is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.Phylloquinone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.Piperacillin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Piroxicam is combined with Canagliflozin.Plerixafor may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Pralatrexate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Pralidoxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Pramipexole is combined with Canagliflozin.Prasugrel may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Prazosin is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Probenecid.Canagliflozin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.Promethazine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Propantheline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Propofol is combined with Canagliflozin.The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Propyphenazone.Canagliflozin may decrease the excretion rate of Pyrantel which could result in a higher serum level.Pyrazinamide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Pyridoxine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Rabeprazole may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Ramelteon may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Ranitidine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Remifentanil is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Resorcinol which could result in a higher serum level.Ribavirin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may increase the hypotensive activities of Risperidone.Rizatriptan may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Roflumilast may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Ropinirole is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Ropivacaine is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Rosuvastatin.The risk or severity of adverse effects can be increased when Rotigotine is combined with Canagliflozin.Ruxolitinib may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Canagliflozin is combined with Sacubitril.The risk or severity of hyperkalemia can be increased when Salicylamide is combined with Canagliflozin.Salmon calcitonin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Salsalate is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Selenious acid which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Selenium which could result in a higher serum level.The risk or severity of adverse effects can be increased when Sevoflurane is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.Sorbitol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may increase the hypotensive activities of Sotatercept.The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Canagliflozin.Sucralfate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Sufentanil is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Sulbactam which could result in a higher serum level.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfamethizole.The risk or severity of hyperkalemia can be increased when Sulindac is combined with Canagliflozin.The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sumatriptan.Canagliflozin may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.Tadalafil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The serum concentration of Talazoparib can be increased when it is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Tamsulosin is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.Teduglutide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Telavancin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Temazepam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Temozolomide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Terazosin is combined with Canagliflozin.Terbutaline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Testosterone may increase the hypoglycemic activities of Canagliflozin.Testosterone cypionate may increase the hypoglycemic activities of Canagliflozin.Testosterone enanthate may increase the hypoglycemic activities of Canagliflozin.Testosterone propionate may increase the hypoglycemic activities of Canagliflozin.Testosterone undecanoate may increase the hypoglycemic activities of Canagliflozin.Tetracycline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.The risk or severity of adverse effects can be increased when Thalidomide is combined with Canagliflozin.The risk or severity of adverse effects can be increased when Thioridazine is combined with Canagliflozin.Ticlopidine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Tinidazole may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Tinzaparin is combined with Canagliflozin.Tiopronin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Tiotropium may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Tirofiban may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Tizanidine is combined with Canagliflozin.Canagliflozin may decrease the excretion rate of Tocopherol which could result in a higher serum level.Canagliflozin may increase the hypotensive activities of Tocopherylquinone.The risk or severity of adverse effects can be increased when Tolcapone is combined with Canagliflozin.The risk or severity of hyperkalemia can be increased when Tolmetin is combined with Canagliflozin.Tolterodine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Topiramate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Tramadol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Trametinib which could result in a higher serum level.Canagliflozin may increase the hypotensive activities of Treprostinil.The risk or severity of adverse effects can be increased when Triamterene is combined with Canagliflozin.Triazolam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Triethylenetetramine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Trifluridine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Canagliflozin.Trimetrexate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Vaborbactam which could result in a higher serum level.The serum concentration of Canagliflozin can be increased when it is combined with Vadadustat.Valaciclovir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Canagliflozin may decrease the excretion rate of Valbenazine which could result in a higher serum level.The risk or severity of hyperkalemia can be increased when Valdecoxib is combined with Canagliflozin.Valganciclovir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Varenicline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Canagliflozin is combined with Vericiguat.Canagliflozin may decrease the excretion rate of Vilanterol which could result in a higher serum level.The metabolism of Canagliflozin can be decreased when combined with Viloxazine.Canagliflozin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.Zaleplon may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Zanamivir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and Invokana®.
Abametapir
Abemaciclib
Amiodarone
Atazanavir
Axitinib
Bendamustine
Binimetinib
Bortezomib
Cabergoline
Carfilzomib
Ceritinib
Clarithromycin
Cobimetinib
Conivaptan
Crizotinib
Curcumin
Cyclosporine
Dacomitinib
Dactinomycin
Danazol
Darunavir
Dasatinib
Elvitegravir
Ergotamine
Etoposide
Gemcitabine
Imipramine
Indinavir
Itraconazole
Ketoconazole
Levoketoconazole
Lonafarnib
Lopinavir
Methimazole
Midostaurin
Mitotane
Nefazodone
Nelfinavir
Nilotinib
Nortriptyline
Osimertinib
Panobinostat
Pomalidomide
Posaconazole
Quinidine
Regorafenib
Ribociclib
Rifapentine
Rimegepant
Romidepsin
Saquinavir
Silodosin
Sirolimus
Spironolactone
Telithromycin
Temsirolimus
Tepotinib
Tipranavir
Tolvaptan
Trastuzumab emtansine
Trimipramine
Venetoclax
Vinblastine
Voriconazole
Abrocitinib
Acarbose
Acebutolol
Acetylsalicylic acid
Adagrasib
Afatinib
Alclometasone
Alogliptin
Ambrisentan
Amcinonide
Amikacin
Aminosalicylic acid
Amitriptyline
Amlodipine
Amobarbital
Amoxapine
Apalutamide
Apixaban
Aprepitant
Aripiprazole
Arsenic trioxide
Articaine
Asciminib
Asenapine
Asunaprevir
Atenolol
Avanafil
Azilsartan medoxomil
Baclofen
Balsalazide
Beclomethasone dipropionate
Belinostat
Belumosudil
Benazepril
Bendroflumethiazide
Berotralstat
Betamethasone
Betaxolol
Betrixaban
Bexagliflozin
Bismuth subsalicylate
Bisoprolol
Bosutinib
Brentuximab vedotin
Brexpiprazole
Bromocriptine
Budesonide
Bumetanide
Butalbital
Candesartan cilexetil
Cannabidiol
Capmatinib
Capreomycin
Captopril
Carbamazepine
Carvedilol
Cenobamate
Chlorothiazide
Chlorpromazine
Chlorthalidone
Choline salicylate
Ciclesonide
Ciprofloxacin
Cisplatin
Citalopram
Clevidipine
Clobazam
Clobetasol propionate
Clocortolone
Clomifene
Clomipramine
Clozapine
Cobicistat
Colchicine
Colistin
Conjugated estrogens
Corticotropin
Cortisone acetate
Dabigatran etexilate
Dabrafenib
Danicopan
Dapagliflozin
Daptomycin
Darolutamide
Dasabuvir
Deferasirox
Deflazacort
Delafloxacin
Desipramine
Desogestrel
Desonide
Desoximetasone
Desvenlafaxine
Dexamethasone
Dexamethasone acetate
Diazoxide
Dienogest
Diflorasone
Diflunisal
Difluprednate
Digoxin
Diltiazem
Diosmin
Dipotassium phosphate
Disopyramide
Dolutegravir
Doxepin
Doxorubicin
Dronedarone
Drospirenone
Dulaglutide
Duvelisib
Edoxaban
Efavirenz
Elacestrant
Elagolix
Elbasvir
Eliglustat
Eltrombopag
Empagliflozin
Enalapril
Enalaprilat
Enasidenib
Encorafenib
Enfortumab vedotin
Entrectinib
Enzalutamide
Epcoritamab
Epinephrine
Eprosartan
Erdafitinib
Ertugliflozin
Erythromycin
Escitalopram
Estetrol
Estradiol
Estrone sulfate
Etacrynic acid
Ethanol
Ethinylestradiol
Ethosuximide
Ethynodiol diacetate
Etonogestrel
Everolimus
Exenatide
Fedratinib
Felodipine
Fexofenadine
Flibanserin
Fluconazole
Fludrocortisone
Flunisolide
Fluocinolone acetonide
Fluocinonide
Fluorometholone
Fluoxetine
Flurandrenolide
Fluticasone furoate
Fluticasone propionate
Fluvoxamine
Fosamprenavir
Fosinopril
Fosnetupitant
Fosphenytoin
Fostemsavir
Furosemide
Fusidic acid
Futibatinib
Gatifloxacin
Gemifloxacin
Gentamicin
Gilteritinib
Glasdegib
Glecaprevir
Glimepiride
Glipizide
Glofitamab
Glyburide
Goserelin
Grazoprevir
Halcinonide
Haloperidol
Histrelin
Hydrochlorothiazide
Hydrocortisone
Hydrocortisone acetate
Hydrocortisone butyrate
Hydrocortisone probutate
Hydrocortisone succinate
Hydrocortisone valerate
Hydroflumethiazide
Hydroxychloroquine
Hydroxyprogesterone caproate
Idelalisib
Iloperidone
Indapamide
Indomethacin
Insulin aspart
Insulin degludec
Insulin detemir
Insulin glargine
Insulin glulisine
Insulin human
Insulin lispro
Irbesartan
Isavuconazonium
Isocarboxazid
Isoniazid
Isradipine
Istradefylline
Ivacaftor
Ivosidenib
Ixabepilone
Labetalol
Lanreotide
Lapatinib
Lasmiditan
Ledipasvir
Lefamulin
Lemborexant
Lenacapavir
Lenvatinib
Leuprolide
Levamlodipine
Levofloxacin
Levomilnacipran
Levonorgestrel
Linagliptin
Linezolid
Liothyronine
Lipoic acid
Liraglutide
Lisinopril
Lixisenatide
Lomefloxacin
Lomitapide
Lonapegsomatropin
Loncastuximab tesirine
Losartan
Loxapine
Lumacaftor
Lurasidone
Lusutrombopag
Magnesium sulfate
Mannitol
Maribavir
Mavacamten
Mavorixafor
Mecasermin
Medroxyprogesterone acetate
Medrysone
Mefenamic acid
Mefloquine
Megestrol acetate
Mesalazine
Methohexital
Methsuximide
Methyl salicylate
Methylene blue
Methylprednisolone
Methylprednisolone hemisuccinate
Metolazone
Metoprolol
Miconazole
Midazolam
Mifepristone
Miglitol
Milnacipran
Mirabegron
Mitapivat
Moexipril
Mometasone furoate
Monopotassium phosphate
Morphine
Moxifloxacin
Nadolol
Naloxegol
Nateglinide
Nebivolol
Neomycin
Neratinib
Netupitant
Niacin
Nicardipine
Nifedipine
Nimodipine
Nintedanib
Nirogacestat
Nisoldipine
Norethisterone
Norgestimate
Octreotide
Ofloxacin
Olanzapine
Olmesartan
Olsalazine
Omadacycline
Ombitasvir
Pacritinib
Palbociclib
Paliperidone
Paritaprevir
Paroxetine
Pasireotide
Pazopanib
Pegvisomant
Pemetrexed
Pentamidine
Pentobarbital
Pentostatin
Perindopril
Phenelzine
Phenobarbital
Phentermine
Phenytoin
Pibrentasvir
Pinaverium
Pindolol
Pioglitazone
Piperine
Pirtobrutinib
Pitolisant
Plazomicin
Polythiazide
Ponatinib
Potassium
Potassium acetate
Potassium bicarbonate
Potassium bitartrate
Potassium carbonate
Potassium cation
Potassium chloride
Potassium citrate
Potassium hydroxide
Potassium Iodide
Potassium nitrate
Potassium sulfate
Potassium triiodide
Pralsetinib
Pramlintide
Pravastatin
Prednicarbate
Prednisolone
Prednisolone acetate
Prednisolone phosphate
Prednisone
Pregabalin
Pretomanid
Primaquine
Primidone
Procainamide
Procaine
Procarbazine
Progesterone
Propafenone
Propranolol
Protriptyline
Prucalopride
Pseudoephedrine
Quetiapine
Quinapril
Quinine
Quizartinib
Ramipril
Ranolazine
Rasagiline
Relugolix
Repaglinide
Repotrectinib
Reserpine
Revefenacin
Rifampin
Rifaximin
Riociguat
Ripretinib
Ritlecitinib
Ritonavir
Rivaroxaban
Rolapitant
Rosiglitazone
Safinamide
Salicylic acid
Sapropterin
Sarecycline
Satralizumab
Saxagliptin
Secobarbital
Selegiline
Selexipag
Selumetinib
Semaglutide
Sertraline
Sildenafil
Simvastatin
Sitagliptin
Sodium ferric gluconate complex
Sodium phosphate, monobasic
Sofosbuvir
Somapacitan
Somatotropin
Somatrogon
Sorafenib
Sotagliflozin
Sotalol
Sotorasib
Sparsentan
Stiripentol
Streptomycin
Sulfadiazine
Sulfamethoxazole
Sulfasalazine
Sunitinib
Suvorexant
Tacrolimus
Tamoxifen
Tazemetostat
Technetium Tc-99m sestamibi
Tegaserod
Telmisartan
Telotristat ethyl
Tenofovir alafenamide
Tenofovir disoproxil
Teprotumumab
Tezacaftor
Thyroid, porcine
Thyrotropin alfa
Ticagrelor
Timolol
Tirzepatide
Tivozanib
Tixocortol
Tobramycin
Tolazamide
Topotecan
Torasemide
Toremifene
Trandolapril
Tranylcypromine
Triamcinolone
Trilaciclib
Triptorelin
Trolamine salicylate
Trovafloxacin
Tucatinib
Ubidecarenone
Ubrogepant
Ulobetasol
Umeclidinium
Valsartan
Vamorolone
Vancomycin
Vandetanib
Vardenafil
Velpatasvir
Vemurafenib
Venlafaxine
Verapamil
Vimseltinib
Vincristine
Voclosporin
Vorapaxar
Vorinostat
Voxilaprevir
Warfarin
Xylometazoline
Ziconotide
Ziprasidone
Zonisamide
Abacavir
Abaloparatide
Aceclofenac
Acetaminophen
Acetazolamide
Acetyl sulfisoxazole
Aclidinium
Acrivastine
Acyclovir
Adefovir dipivoxil
Albuterol
Albutrepenonacog alfa
Aldesleukin
Aliskiren
Allopurinol
Almasilate
Almotriptan
Alprazolam
Amantadine
Amifostine
Amiloride
Ammonium chloride
Amoxicillin
Amphetamine
Amphotericin B
Ampicillin
Amyl Nitrite
Antipyrine
Antithrombin III human
Apomorphine
Apremilast
Aprocitentan
Arformoterol
Aripiprazole lauroxil
Atomoxetine
Auranofin
Azacitidine
Azathioprine
Azelaic acid
Aztreonam
Bacitracin
Baricitinib
Benzatropine
Benznidazole
Bepotastine
Bicisate
Bismuth subgallate
Bleomycin
Bosentan
Bretylium
Brivaracetam
Bromotheophylline
Bupivacaine
Bupropion
Buspirone
Capecitabine
Carbidopa
Carboplatin
Carmustine
Cefaclor
Cefadroxil
Cefazolin
Cefdinir
Cefditoren
Cefepime
Cefotaxime
Cefotetan
Cefoxitin
Cefpodoxime
Cefprozil
Ceftaroline fosamil
Ceftazidime
Ceftibuten
Ceftizoxime
Ceftolozane
Ceftriaxone
Cefuroxime
Celecoxib
Cephalexin
Certolizumab pegol
Cetirizine
Cevimeline
Chloroquine
Chlorzoxazone
Chondroitin sulfate
Chromic chloride
Chromium
Chromium nicotinate
Cidofovir
Cilostazol
Cimetidine
Clofarabine
Clonazepam
Clonidine
Clorazepic acid
Clove oil
Colistimethate
Cyanocobalamin
Dacarbazine
Dalfampridine
Dalteparin
Dantrolene
Dasiglucagon
Deferiprone
Desflurane
Desmopressin
Deutetrabenazine
Dexmedetomidine
Dexpanthenol
Dexrazoxane
Dextran
Diatrizoate
Diazepam
Diclofenac
Diclofenamide
Dicyclomine
Didanosine
Dimercaprol
Dimethyl sulfoxide
Dinutuximab
Dipyridamole
DL-Methylephedrine
Dobutamine
Dopamine
Doxazosin
Doxycycline
Droxidopa
Duloxetine
Edrophonium
Enoxaparin
Ensartinib
Eplerenone
Epoprostenol
Ertapenem
Esmolol
Estazolam
Estradiol acetate
Estradiol cypionate
Estradiol valerate
Eszopiclone
Ethambutol
Ethenzamide
Etodolac
Etomidate
Eucalyptus oil
Evening primrose oil
Fenofibrate
Fenofibric acid
Fenoldopam
Fenoprofen
Fentanyl
Fesoterodine
Finerenone
Fish oil
Flavoxate
Florbetaben F-18
Florbetapir F-18
Floxuridine
Flucytosine
Fludeoxyglucose (18F)
Flumazenil
Fluoxymesterone
Flurazepam
Flurbiprofen
Flutamide
Folic acid
Fomepizole
Fondaparinux
Foscarnet
Fosfomycin
Fostamatinib
Gabapentin enacarbil
Gadobenic acid
Gadodiamide
Gadofosveset trisodium
Gadoteric acid
Gadoteridol
Ganciclovir
Gemfibrozil
Givosiran
Glycerol phenylbutyrate
Golodirsen
Guanfacine
Heparin
Hydralazine
Hydromorphone
Hydroxocobalamin
Hydroxyethyl Starch
Ibuprofen
Ibutilide
Icatibant
Icosapent
Idarucizumab
Ifosfamide
Iloprost
Indigotindisulfonic acid
Inositol
Inotersen
Iobenguane sulfate I-123
Iodixanol
Ioflupane I-123
Iopromide
Iothalamic acid
Ioversol
Ipecac
Ipilimumab
Isoflurane
Isosorbide
Isosorbide dinitrate
Isosorbide mononitrate
Isosulfan blue
Isotretinoin
Isoxsuprine
Ixazomib
Ketamine
Ketoprofen
Ketorolac
Ketotifen
L-Acetylleucine
Lamivudine
Lamotrigine
Landiolol
Lenalidomide
Levocarnitine
Levocetirizine
Levodopa
Levomenthol
Levosalbutamol
Levothyroxine
Lithium carbonate
Lithium citrate
Lofexidine
Loperamide
Lorazepam
Lubiprostone
Macitentan
Magnesium carbonate
Magnesium chloride
Magnesium hydroxide
Magnesium salicylate
Magnesium trisilicate
Maprotiline
Mecamylamine
Meclofenamic acid
Meloxicam
Memantine
Meperidine
Mepivacaine
Meropenem
Metamfetamine
Metaxalone
Methadone
Methazolamide
Methotrexate
Methoxsalen
Methyldopa
Methylnaltrexone
Methyltestosterone
Metoclopramide
Metreleptin
Metyrapone
Metyrosine
Migalastat
Milrinone
Minoxidil
Mycophenolate mofetil
Mycophenolic acid
N-acetyltyrosine
Nabilone
Nabumetone
Naldemedine
Nalmefene
Naloxone
Nandrolone decanoate
Naproxen
Nedocromil
Nilutamide
Nitric Oxide
Nitrofurantoin
Nitroglycerin
Nitroprusside
Nitrous acid
Obinutuzumab
Octinoxate
Omaveloxolone
Opicapone
Opium
Oseltamivir
Oxacillin
Oxandrolone
Oxaprozin
Oxazepam
Oxybenzone
Oxymetholone
Oxyquinoline
Paclitaxel
Palonosetron
Pamidronic acid
Pantoprazole
Papaverine
Parecoxib
Paromomycin
Pentetic acid
Pentoxifylline
Permethrin
Phenazopyridine
Phenoxybenzamine
Phentolamine
Phosphoric acid
Phylloquinone
Picosulfuric acid
Piperacillin
Piroxicam
Plerixafor
Pralatrexate
Pralidoxime
Pramipexole
Prasugrel
Prazosin
Probenecid
Procaine benzylpenicillin
Promethazine
Propantheline
Propofol
Propyphenazone
Pyrantel
Pyrazinamide
Pyridoxine
Rabeprazole
Ramelteon
Ranitidine
Remifentanil
Resorcinol
Ribavirin
Risperidone
Rizatriptan
Roflumilast
Ropinirole
Ropivacaine
Rosuvastatin
Rotigotine
Ruxolitinib
Sacubitril
Salicylamide
Salmon calcitonin
Salsalate
Selenious acid
Selenium
Sevoflurane
Sodium acetate
Sodium fluoride
Sodium sulfate
Solriamfetol
Sorbitol
Sotatercept
Succinylcholine
Sucralfate
Sufentanil
Sulbactam
Sulfamethizole
Sulindac
Sumatriptan
Synthetic Conjugated Estrogens, A
Synthetic Conjugated Estrogens, B
Tadalafil
Talazoparib
Tamsulosin
Tasimelteon
Technetium Tc-99m exametazime
Technetium Tc-99m pyrophosphate
Teduglutide
Telavancin
Temazepam
Temozolomide
Terazosin
Terbutaline
Testosterone
Testosterone cypionate
Testosterone enanthate
Testosterone propionate
Testosterone undecanoate
Tetracycline
Tetradecyl hydrogen sulfate (ester)
Thalidomide
Thioridazine
Ticlopidine
Tinidazole
Tinzaparin
Tiopronin
Tiotropium
Tirofiban
Tizanidine
Tocopherol
Tocopherylquinone
Tolcapone
Tolmetin
Tolterodine
Topiramate
Tramadol
Trametinib
Treprostinil
Triamterene
Triazolam
Triethylenetetramine
Trifluridine
Trimethoprim
Trimetrexate
Vaborbactam
Vadadustat
Valaciclovir
Valbenazine
Valdecoxib
Valganciclovir
Varenicline
Vericiguat
Vilanterol
Viloxazine
Vortioxetine
Zaleplon
Zanamivir